An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of information analysis

M O Soares, N J Welton, D A Harrison, P Peura, M Shankar- Hari, S E Harvey, J J Madan, A E Ades, S J Palmer, K M Rowan

Research output: Contribution to journalArticlepeer-review


Sepsis is a syndrome characterised by a systemic inflammatory response to infection that leads to rapid acute organ failure and potentially rapid decline to death. Intravenous immunoglobulin (IVIG), a blood product derived from human donor blood, has been proposed as an adjuvant therapy for sepsis.
Original languageEnglish
Pages (from-to)1-186
Number of pages186
JournalHealth technology assessment
Issue number7
Publication statusPublished - Feb 2012

Cite this